Modality
siRNA
MOA
CD3xCD20
Target
TNFα
Pathway
Cell Cycle
WilmsSchizophrenia
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
Dec 2019
→ Nov 2027
Phase 3Current
NCT07564375
113 pts·Schizophrenia
2019-12→2027-11·Terminated
NCT06803426
2,073 pts·Wilms
2025-11→2026-05·Active
NCT08818790
2,125 pts·Wilms
2022-05→TBD·Terminated
4,311 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-182mo awayPh3 Readout· Wilms
2027-11-091.6y awayPh3 Readout· Schizophrenia
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P3
Termina…
P3
Termina…
P3
Active
Catalysts
Ph3 Readout
2026-05-18 · 2mo away
Wilms
Ph3 Readout
2027-11-09 · 1.6y away
Schizophrenia
ActiveTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07564375 | Phase 3 | Schizophrenia | Terminated | 113 | HbA1c |
| NCT06803426 | Phase 3 | Wilms | Active | 2073 | DAS28 |
| NCT08818790 | Phase 3 | Wilms | Terminated | 2125 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| ITC-1028 | Intra-Cellular | Phase 2 | BCMA |